S-1 Filing

GUIDED THERAPEUTICS INC CIK: 924515

Filing Information

Form Type	S-1
Accession Number	`0001121781-16-000424`
Period End Date	20151231
Filing Date	20160324
Fiscal Year	N/A
Fiscal Period	N/A
XBRL Instance	gthp-20151231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 94 Income Statement 44 Cash Flow Statement 81 Stockholders Equity 24

Balance Sheet 94 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$76.00K	USD	Point-in-time
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$95.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$613.00K	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$118.00K	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$144.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$35.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$162.00K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $95 and $76 at December 31, 2015 and 2014, respectively	`AccountsReceivableNet`	$190.00K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $95 and $76 at December 31, 2015 and 2014, respectively	`AccountsReceivableNet`	$338.00K	USD	Point-in-time
Inventory, net of reserves of $118 and $144 at December 31, 2015 and 2014, respectively	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$1.18M	USD	Point-in-time
Inventory, net of reserves of $118 and $144 at December 31, 2015 and 2014, respectively	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$1.12M	USD	Point-in-time
Series B convertible preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Series B convertible preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Series B convertible preferred stock, authorized	`PreferredStockSharesAuthorized`	3.00	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$780.00K	USD	Point-in-time
Series B convertible preferred stock, authorized	`PreferredStockSharesAuthorized`	3.00	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$99.00K	USD	Point-in-time
Series B convertible preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$1.78M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$2.12M	USD	Point-in-time
Series B convertible preferred stock, issued	`PreferredStockSharesIssued`	1.20	shares	Point-in-time
Series B convertible preferred stock, outstanding	`PreferredStockSharesOutstanding`	1.20	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$318.00K	USD	Point-in-time
Series B convertible preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$587.00K	USD	Point-in-time
Debt issuance costs	`UnamortizedDebtIssuanceExpense`	$48.00K	USD	Point-in-time
Series B convertible preferred stock, liquidation preference	`PreferredStockLiquidationPreferenceValue`	-	USD	Point-in-time
Series B convertible preferred stock, liquidation preference	`PreferredStockLiquidationPreferenceValue`	$1.20M	USD	Point-in-time
Debt issuance costs	`UnamortizedDebtIssuanceExpense`	$564.00K	USD	Point-in-time
Other assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$101.00K	USD	Point-in-time
Other assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$73.00K	USD	Point-in-time
Series C convertible preferred stock, par value	`SeriesCPreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Series C convertible preferred stock, par value	`SeriesCPreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$806.00K	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.25M	USD	Point-in-time
Series C convertible preferred stock, authorized	`SeriesCPreferredStockSharesAuthorized`	9.00	shares	Point-in-time
Series C convertible preferred stock, authorized	`SeriesCPreferredStockSharesAuthorized`	9.00	shares	Point-in-time
Series C convertible preferred stock, issued	`SeriesCPreferredStockSharesIssued`	5.60	shares	Point-in-time
Series C convertible preferred stock, issued	`SeriesCPreferredStockSharesIssued`	0.00	shares	Point-in-time
TOTAL ASSETS	`Assets`	$3.03M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$2.56M	USD	Point-in-time
Series C convertible preferred stock, outstanding	`SeriesCPreferredStockSharesOutstanding`	5.60	shares	Point-in-time
Series C convertible preferred stock, outstanding	`SeriesCPreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Series C convertible preferred stock, liquidation preference	`SeriesCPreferredStockLiquidationPreferenceValue`	-	USD	Point-in-time
Short-term notes payable, including related parties current portion of long term debt	`ShorttermNotesPayable`	$752.00K	USD	Point-in-time
Short-term notes payable, including related parties current portion of long term debt	`ShorttermNotesPayable`	$646.00K	USD	Point-in-time
Series C convertible preferred stock, liquidation preference	`SeriesCPreferredStockLiquidationPreferenceValue`	$5.55M	USD	Point-in-time
Note payable, in default	`ShortTermBorrowings`	$133.00K	USD	Point-in-time
Note payable, in default	`ShortTermBorrowings`	$123.00K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Short-term convertible notes payable, net of discount	`NotesPayableCurrent`	$1.06M	USD	Point-in-time
Short-term convertible notes payable, net of discount	`NotesPayableCurrent`	$686.00K	USD	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	195,000.00	shares	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	195,000.00	shares	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	2.37M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.73M	USD	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	96,889.00	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.82M	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$1.01M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	96,889.00	shares	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$1.91M	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$217.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$24.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.60M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$5.52M	USD	Point-in-time
Warrants, at fair value	`WarrantsNotSettleableInCashFairValueDisclosure`	$2.07M	USD	Point-in-time
Warrants, at fair value	`WarrantsNotSettleableInCashFairValueDisclosure`	$2.61M	USD	Point-in-time
Long-term debt, net	`LongtermDebtPayableLessCurrentPortion`	$40.00K	USD	Point-in-time
Long-term debt, net	`LongtermDebtPayableLessCurrentPortion`	-	USD	Point-in-time
Convertible note, net of discount	`ConvertibleLongTermNotesPayable`	-	USD	Point-in-time
Convertible note, net of discount	`ConvertibleLongTermNotesPayable`	$783.00K	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$2.61M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$2.89M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$8.12M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$7.50M	USD	Point-in-time
Series B convertible preferred stock, $.001 par value; 3 shares authorized, zero and 1.2 shares issued and outstanding as of December 31, 2015 and 2014, respectively (liquidation preference of none in December 31, 2015 and $1,200 at December 31, 2014, respectively)	`ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue`	$678.00K	USD	Point-in-time
Series B convertible preferred stock, $.001 par value; 3 shares authorized, zero and 1.2 shares issued and outstanding as of December 31, 2015 and 2014, respectively (liquidation preference of none in December 31, 2015 and $1,200 at December 31, 2014, respectively)	`ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue`	-	USD	Point-in-time
Series C convertible preferred stock, $.001 par value; 9.0 shares authorized, 5.6 shares issued and outstanding as of December 31, 2015 and none authorized or issued and outstanding at December 31, 2014. (Liquidation preference of $5,555 at December 31, 2015 and none at December 31, 2014).	`ConvertiblePreferredStockSeriesCNonredeemableOrRedeemableIssuerOptionValue`	$2.05M	USD	Point-in-time
Series C convertible preferred stock, $.001 par value; 9.0 shares authorized, 5.6 shares issued and outstanding as of December 31, 2015 and none authorized or issued and outstanding at December 31, 2014. (Liquidation preference of $5,555 at December 31, 2015 and none at December 31, 2014).	`ConvertiblePreferredStockSeriesCNonredeemableOrRedeemableIssuerOptionValue`	-	USD	Point-in-time
Common stock, $.001 par value; 1,000,000 and 195,000 shares authorized, 2,371 and 969 shares issued and outstanding as of December 31, 2015 and 2014, respectively	`CommonStockValue`	$97.00K	USD	Point-in-time
Common stock, $.001 par value; 1,000,000 and 195,000 shares authorized, 2,371 and 969 shares issued and outstanding as of December 31, 2015 and 2014, respectively	`CommonStockValue`	$236.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$114.84M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$107.95M	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$132.00K	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$132.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-122.56M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-113.06M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' DEFICIT	`TotalGuidedTherapeuticsStockholdersEquity`	$-5.56M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' DEFICIT	`TotalGuidedTherapeuticsStockholdersEquity`	$-4.46M	USD	Point-in-time
TOTAL STOCKHOLDERS DEFICIT	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-5.56M	USD	Point-in-time
TOTAL STOCKHOLDERS DEFICIT	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-4.46M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	`LiabilitiesAndStockholdersEquity`	$3.03M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	`LiabilitiesAndStockholdersEquity`	$2.56M	USD	Point-in-time

Income Statement 44 line items

Line Item	Tag	Value	Unit	Period
Sales - devices and disposables	`SalesDevicesAndDisposables`	$758.00K	USD	Annual
Sales - devices and disposables	`SalesDevicesAndDisposables`	$564.00K	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$891.00K	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$537.00K	USD	Annual
Gross Profit (loss)	`GrossProfit`	$27.00K	USD	Annual
Gross Profit (loss)	`GrossProfit`	$-133.00K	USD	Annual
Contract and grant revenue	`Revenues`	$65.00K	USD	Annual
Contract and grant revenue	`Revenues`	$42.00K	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.48M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.79M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$718.00K	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$1.16M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.65M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.10M	USD	Annual
Total operating expenses	`OperatingExpenses`	$8.60M	USD	Annual
Total operating expenses	`OperatingExpenses`	$6.30M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-8.67M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-6.23M	USD	Annual
Other income	`OtherIncome`	$25.00K	USD	Annual
Other income	`OtherIncome`	$74.00K	USD	Annual
Interest expense	`InterestExpense`	$979.00K	USD	Annual
Interest expense	`InterestExpense`	$1.32M	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-325.00K	USD	Annual
Change in fair value of warrants	`DerivativeGainLossOnDerivativeNet`	$65.00K	USD	Annual
Change in fair value of warrants	`DerivativeGainLossOnDerivativeNet`	$568.00K	USD	Annual
Total other expenses	`TotalOtherIncome`	$-675.00K	USD	Annual
Total other expenses	`TotalOtherIncome`	$-1.21M	USD	Annual
LOSS FROM OPERATIONS	`LossBeforeIncomeTaxes`	$9.88M	USD	Annual
LOSS FROM OPERATIONS	`LossBeforeIncomeTaxes`	$6.90M	USD	Annual
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	Annual
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	Annual
NET LOSS	`NetIncomeLoss`	$-9.88M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-6.90M	USD	Annual
DEEMED DIVIDENDS	`InvestmentIncomeDividend`	-	USD	Annual
DEEMED DIVIDENDS	`InvestmentIncomeDividend`	$-1.26M	USD	Annual
PREFERRED STOCK DIVIDENDS	`PreferredStockDividendsIncomeStatementImpact`	$-152.00K	USD	Annual
PREFERRED STOCK DIVIDENDS	`PreferredStockDividendsIncomeStatementImpact`	$-1.34M	USD	Annual
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-10.04M	USD	Annual
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-9.50M	USD	Annual
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS (post 1:100 reverse stock split)	`EarningsPerShareBasicAndDiluted`	$-7.42	USD	Annual
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS (post 1:100 reverse stock split)	`EarningsPerShareBasicAndDiluted`	$-13.02	USD	Annual
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	771.00	shares	Annual
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	1,280.00	shares	Annual

Cash Flow Statement 81 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-9.88M	USD	Annual
Net loss	`NetIncomeLoss`	$-6.90M	USD	Annual
Bad debt expense	`BadDebtRecovery`	$19.00K	USD	Annual
Bad debt expense	`BadDebtRecovery`	$63.00K	USD	Annual
Depreciation and Amortization	`DepreciationDepletionAndAmortization`	$1.24M	USD	Annual
Depreciation and Amortization	`DepreciationDepletionAndAmortization`	$1.05M	USD	Annual
Stock based compensation	`ShareBasedCompensation`	$886.00K	USD	Annual
Stock based compensation	`ShareBasedCompensation`	$1.01M	USD	Annual
Non-employee stock based compensation	`NonemployeeShareBasedCompensation`	-	USD	Annual
Non-employee stock based compensation	`NonemployeeShareBasedCompensation`	$400.00K	USD	Annual
Change in fair value of warrants	`ChangeInFairValueOfWarrants`	$-568.00K	USD	Annual
Change in fair value of warrants	`ChangeInFairValueOfWarrants`	$-65.00K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$267.00K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-129.00K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$-14.00K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$-61.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$681.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-2.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-254.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-28.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$842.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$91.00K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$10.00K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$193.00K	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$296.00K	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$1.12M	USD	Annual
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$2.86M	USD	Annual
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$3.60M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-6.28M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-4.04M	USD	Annual
Additions to fixed assets	`AdditionsToFixedAssets`	$-8.00K	USD	Annual
Additions to fixed assets	`AdditionsToFixedAssets`	$-150.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-8.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-150.00K	USD	Annual
Net proceeds from issuance of preferred stock and warrants, net	`ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants`	$3.70M	USD	Annual
Net proceeds from issuance of preferred stock and warrants, net	`ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants`	-	USD	Annual
Net proceeds from issuance of common stock and warrants, net	`ProceedsFromIssuanceOfCommonStock`	$720.00K	USD	Annual
Net proceeds from issuance of common stock and warrants, net	`ProceedsFromIssuanceOfCommonStock`	$1.73M	USD	Annual
Proceeds from debt financing, net of discount	`ProceedsFromIssuanceOfDebt`	$5.26M	USD	Annual
Proceeds from debt financing, net of discount	`ProceedsFromIssuanceOfDebt`	$425.00K	USD	Annual
Payment for debt issuance costs	`PaymentsOfDebtIssuanceCosts`	$48.00K	USD	Annual
Payment for debt issuance costs	`PaymentsOfDebtIssuanceCosts`	$452.00K	USD	Annual
Payments on notes	`PaymentsOfLoanCosts`	$1.01M	USD	Annual
Payments on notes	`PaymentsOfLoanCosts`	$656.00K	USD	Annual
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$143.00K	USD	Annual
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$97.00K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$3.92M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.98M	USD	Annual
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-451.00K	USD	Annual
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-127.00K	USD	Annual
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$613.00K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$35.00K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$162.00K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of year	`Cash`	$35.00K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of year	`Cash`	$162.00K	USD	Point-in-time
Cash paid for Interest	`InterestPaid`	$33.00K	USD	Annual
Cash paid for Interest	`InterestPaid`	$76.00K	USD	Annual
Deemed dividend on beneficial conversion features of Series C Preferred stock	`DeemedDividendOnBeneficialConversionFeaturesOfSeriesCPreferredStock`	-	USD	Annual
Deemed dividend on beneficial conversion features of Series C Preferred stock	`DeemedDividendOnBeneficialConversionFeaturesOfSeriesCPreferredStock`	$150.00K	USD	Annual
Deemed dividend on price changes for Series B preferred stock warrants	`DeemedDividendOnPriceChangesForSeriesBPreferredStockWarrants`	$64.00K	USD	Annual
Deemed dividend on price changes for Series B preferred stock warrants	`DeemedDividendOnPriceChangesForSeriesBPreferredStockWarrants`	-	USD	Annual
Deemed dividend on December 2014 public offering warrants	`DeemedDividendPublicOfferingWarrants`	$1.05M	USD	Annual
Deemed dividend on December 2014 public offering warrants	`DeemedDividendPublicOfferingWarrants`	-	USD	Annual
Term changes on Series B preferred stock and December 2014 public offering warrant resulting in transfer to equity	`TermChangesOnSeriesBPreferredStockPublicOfferingWarrant`	-	USD	Annual
Term changes on Series B preferred stock and December 2014 public offering warrant resulting in transfer to equity	`TermChangesOnSeriesBPreferredStockPublicOfferingWarrant`	$324.00K	USD	Annual
Issuance of common stock as debt repayment	`IssuanceOfCommonStockAsDebtRepayment`	$1.01M	USD	Annual
Issuance of common stock as debt repayment	`IssuanceOfCommonStockAsDebtRepayment`	-	USD	Annual
Repayment of deferred compensation via issuance of preferred stock	`RepaymentOfDeferredCompensationViaIssuanceOfPreferredStock`	-	USD	Annual
Repayment of deferred compensation via issuance of preferred stock	`RepaymentOfDeferredCompensationViaIssuanceOfPreferredStock`	$100.00K	USD	Annual
Dividends on preferred stock	`DividendsOnPreferredStock`	$152.00K	USD	Annual
Dividends on preferred stock	`DividendsOnPreferredStock`	$1.34M	USD	Annual
Conversion of accrued expenses into common stock	`ConversionOfAccruedExpensesIntoCommonStock`	-	USD	Annual
Conversion of accrued expenses into common stock	`ConversionOfAccruedExpensesIntoCommonStock`	$207.00K	USD	Annual
Payment of debt issuance costs via warrants and common stock	`PaymentOfDebtIssuanceCostsViaWarrantsAndCommonStock`	$522.00K	USD	Annual
Payment of debt issuance costs via warrants and common stock	`PaymentOfDebtIssuanceCostsViaWarrantsAndCommonStock`	-	USD	Annual
Conversion of convertible debt into common stock	`ConversionOfConvertibleDebtIntoCommonStock`	$893.00K	USD	Annual
Conversion of convertible debt into common stock	`ConversionOfConvertibleDebtIntoCommonStock`	-	USD	Annual
Repayment of debt via issuance of common stock and warrants	`RepaymentOfDebtViaIssuanceOfCommonStockAndWarrants`	-	USD	Annual
Repayment of debt via issuance of common stock and warrants	`RepaymentOfDebtViaIssuanceOfCommonStockAndWarrants`	$1.70M	USD	Annual
Issuance of common stock as board compensation	`IssuanceOfCommonStockAsBoardCompensation`	-	USD	Annual
Issuance of common stock as board compensation	`IssuanceOfCommonStockAsBoardCompensation`	$355.00K	USD	Annual

Stockholders Equity 24 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, Amount	`StockholdersEquity`	$-4.46M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$-5.56M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$-107.00K	USD	Point-in-time
Preferred dividends	`PreferredDividends`	$-352.00K	USD	Annual
Preferred dividends	`PreferredDividends`	$-152.00K	USD	Annual
Conversion of preferred stock, Amount	`ConversionOfPreferredStockAmount`	-	USD	Annual
Issuance of common stock and warrants, Amount	`IssuanceOfCommonStockAndWarrants`	$433.00K	USD	Annual
Issuance of common stock and warrants, Amount	`IssuanceOfCommonStockAndWarrants`	$1.34M	USD	Annual
Conversion of Series C preferred stock to common stock, Amount	`ConversionOfSeriesCPreferredStockToCommonStockAmount`	-	USD	Annual
Issuance of stock options	`IssuanceOfStockOptions`	$61.00K	USD	Annual
Exercise of warrants and options into common stock, Amount	`ExerciseOfWarrantsoptionsAmount`	$96.00K	USD	Annual
Exercise of warrants and options into common stock, Amount	`ExerciseOfWarrantsoptionsAmount`	$143.00K	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$886.00K	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$1.01M	USD	Annual
Conversion of debts into common stock, Amount	`ConversionOfDebtsIntoCommonStockAmount`	$893.00K	USD	Annual
Conversion of debts into common stock, Amount	`ConversionOfDebtsIntoCommonStockAmount`	$1.01M	USD	Annual
December 2014 public offering warrants exchange and common shares issuance, Amount	`December2014PublicOfferingWarrantsExchangeAndCommonSharesIssuanceAmount`	$322.00K	USD	Annual
Series B, Tranche A, warrant price adjustment	`SeriesBTrancheWarrantPriceAdjustment`	-	USD	Annual
Series C preferred stock and warrant issuance, Amount	`SeriesCPreferredStockAndWarrantIssuanceAmount`	$2.33M	USD	Annual
Net Loss	`NetIncomeLoss`	$-9.88M	USD	Annual
Net Loss	`NetIncomeLoss`	$-6.90M	USD	Annual
Ending Balance, Amount	`StockholdersEquity`	$-4.46M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$-5.56M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$-107.00K	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.